Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01563484|
Recruitment Status : Unknown
Verified March 2012 by Li Chen, Southeast University, China.
Recruitment status was: Active, not recruiting
First Posted : March 27, 2012
Last Update Posted : April 2, 2012
|Condition or disease|
|Primary Hepatocellular Carcinoma|
This was a prospective, randomized, single centre, single-blind study. Patients were randomized (1:1) to use Low-osmolar contrast media or iso-osmolar contrast media for TACE.
On the morning of 2th and 5th days after TACE, a hematologic check was performed, the hematologic check including serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase. Then, comparing them with the data before TACE.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Observational Model:||Case Control|
|Official Title:||Comparison of Liver and Renal Function After TACE for PHC With Iso-osmolar and Low-osmolar Contrast Media|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||September 2012|
|Estimated Study Completion Date :||September 2012|
low-osmolar contrast media
Patients undergo TACE of low-osmolar contrast media on day 1.
iso-osmolar contrast media
Patients undergo TACE of iso-osmolar contrast media on day 1.
- Change from Baseline in serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase. [ Time Frame: Follow-up on the 2th and 5th days after TACE ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563484
|Zhongda Hospital, Southeast University|
|Nanjing, Jiangsu, China, 210009|
|Principal Investigator:||Gao-Jun Teng, MD||Medical School,Southeast University|